Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 6:10:225-236.
doi: 10.2147/ITT.S288546. eCollection 2021.

Targeting CD22 for the Treatment of B-Cell Malignancies

Nikesh N Shah  1 , Lubomir Sokol  2
Affiliations
Review

Targeting CD22 for the Treatment of B-Cell Malignancies

Nikesh N Shah et al. Immunotargets Ther. .

Abstract

Immunotherapeutic agents play an increasingly important role in the treatment of B-cell malignancies. CD19 and CD20 are common targets for lymphoid malignancies, though patients who relapse have few therapeutic options remaining. CD22 is a cell surface sialoglycoprotein uniquely present on B-cells and regulates B-cell function and proliferation. Thus, it is an appealing therapeutic target for autoimmune disorders and B-cell malignancies. A variety of therapies targeting CD22 have been developed, including monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, chimeric antigen receptor T cells, and bispecific antibodies. Here, we review the biology of CD22 and key therapies targeting CD22 in lymphoid malignancies.

Keywords: CD22; acute lymphoblastic leukemia; bispecific antibody; chimeric antigen receptor; epratuzumab; inotuzumab ozogamicin; lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors reported no conflicts of interest for this work.

Figures

Figure 1
Figure 1
Legend: Simplified schema depicting current therapies targeting CD22 in B-cell malignancies. (A) Naked antibody; (B) Antibody-drug conjugate; (C) Radioimmunoconjugate; (D) Bispecific antibody/bispecific T-cell engager; (E) Chimeric antigen receptor (CAR)-T cell; (F) Bispecific CAR-T cell; (G) Tandem bispecific CAR-T cell. Abbreviations: 90Y, Yttrium-90. Figure created with BioRender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459. doi:10.3322/caac.21357 - DOI - PubMed
    1. Morrison VA, Hong F, Habermann TM, et al. R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): long-Term Follow-up of Intergroup E4494/C9793. Blood. 2010;116:589. doi:10.1182/blood.V116.21.589.589 - DOI
    1. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377(14):1331–1344. doi:10.1056/NEJMoa1614598 - DOI - PubMed
    1. Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther. 2006;6(10):1341–1353. doi:10.1586/14737140.6.10.1341 - DOI - PubMed
    1. Doody GM, Justement LB, Delibrias CC, et al. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science. 1995;269(5221):242–244. doi:10.1126/science.7618087 - DOI - PubMed

Grants and funding

No funding was utilized for this systematic review.